InsidersTradesSigma
Pacira BioSciences, Inc. Stock: price and directors' dealings · United States · SEC (Form 4)
Track the Pacira BioSciences, Inc. share price and the full directors' dealings record of the company, a listed issuer based in United States. Shares trade on US US, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pacira BioSciences, Inc. has logged 221 public disclosures. Market capitalisation: €999m. The latest transaction was filed on 12 June 2026 (Attribution). Among the most active insiders: SLONIN JONATHAN. The full history is openly available.
221
Insider Decl.
0
Thresholds
€234,293
7 ops.
Buy Volume
€7m
65 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Pacira BioSciences, Inc. Buy (bullish), based on 6 analysts. Average price target: US$29.67.
41Σ signal
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Fundamental score
Ranked 12,920 of 25,535 companies
51.5
score / 100
Value57
Quality46
FCF yld14%
Earn yld0.7%
EV/EBITDA11.6x
ROE0.7%
Gross mgn79%
Net mgn1.0%
Debt/EBITDA3.4x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
Last declaration on 12 June 2026
Declarations221 total
6,405 sharesCommon StockSEC:0001628280-26-043004:0
6,405 sharesCommon StockSEC:0001628280-26-043002:0
6,405 sharesCommon StockSEC:0001628280-26-043008:0
17,134 shares@ US$20.5450.0% of flowCommon StockSEC:0001628280-26-005157
2,751 shares@ US$20.5446.7% of flowCommon StockSEC:0001628280-26-005158
2,751 shares@ US$20.540.0044% mcap46.7% of flowCommon StockSEC:0001628280-26-005158:0
17,134 shares@ US$20.540.028% mcap50.0% of flowCommon StockSEC:0001628280-26-005157:0
159 shares@ US$24.463.3% of flowCommon StockSEC:0001628280-26-000967
159 shares@ US$24.460.0003% mcap3.3% of flowCommon StockSEC:0001628280-26-000967:0
2,354 shares@ US$27.190.0052% mcap50.0% of flowCommon StockSEC:0001396814-25-000109:0
2,354 shares@ US$27.1950.0% of flowCommon StockSEC:0001396814-25-000109
79,200 shares0Common StockSEC:0001396814-25-000032:0
54,000 shares0Common StockSEC:0001396814-25-000030:0
30,600 shares0Common StockSEC:0001396814-25-000029:0
93,600 shares0Common StockSEC:0001396814-25-000033:0
350,000 shares0Common StockSEC:0001396814-25-000031:0
9,375 shares@ US$18.3364.5% of flowCommon StockSEC:0001396814-25-000008:0
243.537 shares@ US$16.0141.3% of flowCommon StockSEC:0001396814-25-000006:0
159 shares@ US$18.331.8% of flowCommon StockSEC:0001396814-25-000005:0
371 shares@ US$18.331.6% of flowCommon StockSEC:0001396814-25-000007:0
500 shares@ US$19.763.4% of flowCommon StockSEC:0001396814-24-000143:0
75,000 shares0Common StockSEC:0001396814-24-000135:0
500 shares@ US$12.862.1% of flowCommon StockSEC:0001396814-24-000122:0
1,000 shares@ US$12.815.2% of flowCommon StockSEC:0001396814-24-000117:0
Ideal exit: 13 May 2025 (T+270)
1,512 shares@ US$13.2519.6% of flowCommon StockSEC:0001396814-24-000118:0
Ideal exit: 13 May 2025 (T+270)
25 of 221 declarations
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ (United States) and focused on non-opioid pain management. The company’s commercial platform is built around injectable therapies and cryoneurolysis solutions used mainly in hospital and outpatient settings. Pacira’s core franchise is EXPAREL, its liposomal bupivacaine product, which has long served as the company’s primary revenue driver. The portfolio was broadened through the acquisition of iovera° in 2019 and ZILRETTA, an extended-release triamcinolone injectable suspension. Strategically, Pacira positions itself as a leader in reducing opioid reliance in perioperative care and selected orthopedic pain indications. ([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-completes-acquisition-myoscience-advancing-leadership-non)) The company is headquartered in Brisbane, California, placing it in a major U.S. life sciences hub. Its business model combines direct commercialization, product revenue generation, and an expanding set of licensing and partnership agreements. In 2024, Pacira reported $697.2 million of net product sales, led by EXPAREL, followed by ZILRETTA and iovera°. That mix highlights a concentrated but meaningful specialty-pharma revenue base, with a small number of branded assets carrying most of the financial performance. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1396814/000110465925041234/tm254483d2_ars.pdf)) From a competitive standpoint, Pacira is differentiated by its non-opioid positioning in a market where demand for opioid-sparing pain solutions remains structurally important in the United States. EXPAREL is supported by proprietary DepoFoam delivery technology, while iovera° offers targeted cryoneurolysis to temporarily interrupt pain signaling. ZILRETTA adds an orthopedics-oriented asset with relevance in osteoarthritis and related pain management. Together, these products give Pacira a niche leadership position in a specialized therapeutic area where clinical adoption, reimbursement, and differentiated product performance matter more than broad primary-care scale. ([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-completes-acquisition-myoscience-advancing-leadership-non)) Recent developments suggest improving commercial momentum. In the fourth quarter of 2025, Pacira reported revenue of $196.9 million and record-high EXPAREL sales, while iovera° also grew year over year. In November 2025, the company announced an exclusive worldwide license agreement with AmacaThera for AMT-143, a long-acting ropivacaine formulation for postsurgical pain, indicating continued pipeline and business-development activity. The company also continued share repurchases, reinforcing a capital-allocation focus alongside operating execution. For investors, Pacira represents a NASDAQ-listed U.S. healthcare name with exposure to the growing non-opioid pain market, balanced by concentration risk across a limited number of flagship products. ([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-biosciences-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
